|
Daily Medical Update
Acute Coronary Syndrome Complications
Sunday, May 24, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Medicina (Kaunas, Lithuania) (2025) - Meta-Analysis
Key Findings
- Initiation of SGLT2 inhibitors after ACS was associated with lower all-cause mortality (HR 0.77, 95% CI 0.67-0.89) and cardiovascular mortality (HR 0.83, 95% CI 0.70-0.99).
- Among patients with type 2 diabetes, recurrent myocardial infarction was also reduced (HR 0.83, 95% CI 0.69-0.99), while non-diabetic subgroup effects were not significant.
📋 Practice Implication: After ACS, SGLT2 inhibitors appear most actionable for eligible patients with type 2 diabetes because the recurrent MI signal was concentrated there rather than across all-comers.
|
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025) - Meta-Analysis
Key Findings
- Complete revascularization reduced all-cause death versus culprit-only PCI (RR 0.86, 95% CI 0.74-1.00) and lowered cardiovascular mortality by 26%.
- New myocardial infarction and unplanned revascularization were reduced without significant increases in major bleeding, contrast-induced nephropathy, or stroke, although stent thrombosis was higher (RR 1.69, 95% CI 1.10-2.59).
📋 Practice Implication: For ACS with multivessel disease, a complete revascularization plan should usually be pursued unless anatomy or instability makes the added stent-thrombosis tradeoff unacceptable.
|
The American journal of cardiology (2026) - Meta-Analysis
Key Findings
- ACS patients with active cancer had higher in-hospital mortality (RR 2.56, 95% CI 1.07-6.15), higher long-term mortality (RR 3.55, 95% CI 1.71-7.36), and higher bleeding risk (RR 1.47) than patients without cancer.
- The excess in-hospital mortality was significant in patients not undergoing PCI (RR 4.02) but was not significant in the PCI group (RR 1.45), and long-term mortality remained lower with PCI than without PCI (RR 2.16 vs 6.13).
📋 Practice Implication: Active cancer should trigger earlier multidisciplinary planning after ACS, because deferring PCI may worsen short-term mortality even when bleeding risk is elevated.
|
American journal of therapeutics (2025) - Meta-Analysis
Key Findings
- Post-ACS SGLT2 inhibitor use reduced first heart failure hospitalization (RR 0.78, 95% CI 0.66-0.92) and stroke (RR 0.56, 95% CI 0.35-0.90).
- Cardiac death was also lower (RR 0.84, 95% CI 0.74-0.96), while all-cause mortality was not significantly changed.
📋 Practice Implication: In post-ACS patients with heart-failure-prone features, SGLT2 inhibitors can be prioritized to prevent decompensation and stroke even when an all-cause mortality benefit is not yet proven.
|
ESC heart failure (2026) - Meta-Analysis
Key Findings
- Starting a mineralocorticoid receptor antagonist within 60 days after decompensation or acute MI with left ventricular dysfunction reduced all-cause death (RR 0.87, 95% CI 0.79-0.95) and worsening heart failure (RR 0.81, 95% CI 0.72-0.91).
- Early treatment did not increase worsening renal failure or hypotension, but it did increase hyperkalemia risk while reducing hypokalemia (RR 0.39, 95% CI 0.26-0.58).
📋 Practice Implication: After ACS complicated by new ventricular dysfunction, early MRA initiation deserves prompt follow-up lab monitoring rather than delayed prescribing, because the mortality and HF benefits were paired mainly with a potassium-management burden.
|
|
💡
Summary
Recent meta-analyses on ACS complications emphasize two practical themes: aggressive secondary prevention after the index event can reduce death, recurrent ischemia, and heart failure events, while selected invasive strategies remain important for high-risk subgroups. Patients with multivessel disease, active cancer, or new left ventricular dysfunction appear to carry materially different risk profiles that should shape revascularization and medication choices during early follow-up.
|
|